Two-Weekly or Three-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Young Patients with Good-Prognosis (Normal LDH) Aggressive Lymphomas: Results of the NHL-B1 Trial of the DSHNHL

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Poeschel V.
Held G.
Ziepert M.
Witzens-Harig M.
Holte H.
Thurner L.
Borchmann P.
Viardot A.
Soekler M.
Keller U.
Schmidt C.
Truemper L.
Mahlberg R.
Marks R.
Hoeffkes H. -G.
Metzner B.
Dierlamm J.
Frickhofen N.
Haenel M.
Neubauer A.
Kneba M.
Merli F.
Tucci A.
de Nully Brown P.
Federico M.
Lengfelder E.
di Rocco A.
Trappe R.
Rosenwald A.
Berdel C.
Maisenhoelder M.
Shpilberg O.
Amam J.
Christofyllakis K.
Hartmann F.
Murawski N.
Stilgenbauer S.
Nickelsen M.
Wulf G.
Glass B.
Schmitz N.
Altmann B.
Loeffler M.
Pfreundschuh M.

January 2019

Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma

Tilly, H.
Lepage, E.
Coiffier, B.
Blanc, M.
Herbrecht, R.
Bosly, André
Attal, M.
Fillet, G.
Guettier, C.
Molina, TJ
Gisselbrecht, C.
Reyes, F.

January 2003

We conducted a randomized trial to compare the intensive conventional chemotherapy regimen ACVBP (do...

Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma

Burton, C.
Smith, P.
Vaughan-Hudson, G.
Qian, W.
Hoskin, P.
Cunningham, D.
Hancock, B.
Linch, D.

July 2005

CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) has been the standard chemotherap...

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Two-weekly or 3-weekly CHOP

Michael Pfreundschuh
Marita Kloess
Rudolf Schmits
Alfred C. Feller
Christian Rudolph
Marcel Reiser
Dieter K. Hossfeld
Bernd Metzner
Dirk Hasenclever
Norbert Schmitz
Bertram Glass
Markus Loeffler
For The German

September 2016

chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (norm...

Etoposide and idarubicin in a modified CHOP-like regimen (VICED) for aggressive non-Hodgkin's lymphomas.

A. De Renzo
R. Notaro
L. Pezzullo
A. D'Arco
D. Pagnini
B. Rotoli
PETTINATO, GUIDO

January 1998

The superiority of intensive versus standard chemotherapy for aggressive (I: intermediate; H: high g...

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

Glass, B
Kloess, M
Bentz, M
Schlimok, G
Berdel, WE
Feller, A
Trumper, L
Loeffler, M
Pfreundschuh, M
Schmitz, N

April 2006

Feasibility, safety, and efficacy of a 4-course high-dose chemotherapy (HDT) protocol including auto...

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Verdonck, L.F.
Notenboom, A.
Jong, D.D. de
MacKenzie, M.A.
Verhoef, G.E.
Kramer, M.H.
Ossenkoppele, G.J.
Doorduijn, J.K.
Sonneveld, P.
Imhoff, G.W. van

January 2007

Contains fulltext : 53318.pdf (publisher's version ) (Closed access)Optimal dose a...

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma

Herve ́ Tilly
Eric Lepage
Michel Blanc
Raoul Herbrecht
Andre ́ Bosly
Michel Attal
Georges Fillet
Catherine Guettier
Thierry Jo Molina
Christian Gisselbrecht

September 2016

We conducted a randomized trial to com-pare the intensive conventional chemo-therapy regimen ACVBP (...

CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma - a meta-analysis of randomized controlled trials

Vidal, Liat
Shpilberg, Ofer
Gurion, Ronit
Monsef, Ina
Raanani, Pia
Ram, Ron
Gafter-Gvili, Anat

January 2016

Background. R-CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma. ...

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study

Kluin-Nelemans, HC
Zagonel, V.
Anastasopoulou, A
Bron, D
Roozendaal, KJ
Noordijk, EM
Musson, H
Teodorovic, I.
Maes, B
Carbone, A
Carde, P

January 2001

Background: The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor....

Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin’s Lymphoma: Randomized Phase III EORTC Study

Hanneke C. Kluin-nelemans
Vittorina Zagonel
Anastasia Anastasopoulou
Dominique Bron
Klaas J. Roozendaal
M. Noordijk
Helen Musson
Brigitte Maes
Antonino Carbone
Patrice Carde
Jose ́ Thomas

July 2015

Background: The long-term outcome for patients with ag-gressive non-Hodgkin’s lymphoma (NHL) is poor...

Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMET) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma

Bailey, N. P.
Stuart, N. S. A.
Bessell, E. M.
Child, J. A.
Norfolk, D.
Fletcher, J.
Grieve, R. J.
Simmons, A. V.
Barnard, D. L.
Jack, A.
Farish, J.
Dunn, Janet A.
Woodroffe, C. M.
Stack, C.
Cullen, M. H.

June 1998

Background: Weekly alternating regimen known as CAPOMEt is compared to standard cyclical chemothera...

Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.

Wästerlid, Tove
Werner Hartman, Linda
Szekely, Erzsébet
Jerkeman, Mats

September 2015

No randomised study in the rituximab era has been performed specifically to evaluate addition of eto...

High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)

A. Wunderlich
M. Kloess
M. Reiser
C. Rudolph
L. Truemper
S. Bittner
H. Schmalenberg
R. Schmits
M. Pfreundschuh
M. Loeffler

January 2002

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for ...

Alternating CHOPB-POEMB chemotherapy for intermediate- and high-grade non-Hodgkin's lymphomas

Mizuta, Jun

December 1993

Between 1986 and 1991, 45 patients with intermediate- or high-grade non-Hodgkin's lymphoma, includin...

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Poeschel V.
Held G.
Ziepert M.
Witzens-Harig M.
Holte H.
Thurner L.
Borchmann P.
Viardot A.
Soekler M.
Keller U.
Schmidt C.
Truemper L.
Mahlberg R.
Marks R.
Hoeffkes H. -G.
Metzner B.
Dierlamm J.
Frickhofen N.
Haenel M.
Neubauer A.
Kneba M.
Merli F.
Tucci A.
de Nully Brown P.
Federico M.
Lengfelder E.
di Rocco A.
Trappe R.
Rosenwald A.
Berdel C.
Maisenhoelder M.
Shpilberg O.
Amam J.
Christofyllakis K.
Hartmann F.
Murawski N.
Stilgenbauer S.
Nickelsen M.
Wulf G.
Glass B.
Schmitz N.
Altmann B.
Loeffler M.
Pfreundschuh M.

January 2019

Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma

Tilly, H.
Lepage, E.
Coiffier, B.
Blanc, M.
Herbrecht, R.
Bosly, André
Attal, M.
Fillet, G.
Guettier, C.
Molina, TJ
Gisselbrecht, C.
Reyes, F.

January 2003

We conducted a randomized trial to compare the intensive conventional chemotherapy regimen ACVBP (do...

Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma

Burton, C.
Smith, P.
Vaughan-Hudson, G.
Qian, W.
Hoskin, P.
Cunningham, D.
Hancock, B.
Linch, D.

July 2005

CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) has been the standard chemotherap...

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Two-weekly or 3-weekly CHOP

Michael Pfreundschuh
Marita Kloess
Rudolf Schmits
Alfred C. Feller
Christian Rudolph
Marcel Reiser
Dieter K. Hossfeld
Bernd Metzner
Dirk Hasenclever
Norbert Schmitz
Bertram Glass
Markus Loeffler
For The German

September 2016

chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (norm...

Etoposide and idarubicin in a modified CHOP-like regimen (VICED) for aggressive non-Hodgkin's lymphomas.

A. De Renzo
R. Notaro
L. Pezzullo
A. D'Arco
D. Pagnini
B. Rotoli
PETTINATO, GUIDO

January 1998

The superiority of intensive versus standard chemotherapy for aggressive (I: intermediate; H: high g...

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

Glass, B
Kloess, M
Bentz, M
Schlimok, G
Berdel, WE
Feller, A
Trumper, L
Loeffler, M
Pfreundschuh, M
Schmitz, N

April 2006

Feasibility, safety, and efficacy of a 4-course high-dose chemotherapy (HDT) protocol including auto...

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Verdonck, L.F.
Notenboom, A.
Jong, D.D. de
MacKenzie, M.A.
Verhoef, G.E.
Kramer, M.H.
Ossenkoppele, G.J.
Doorduijn, J.K.
Sonneveld, P.
Imhoff, G.W. van

January 2007

Contains fulltext : 53318.pdf (publisher's version ) (Closed access)Optimal dose a...

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma

Herve ́ Tilly
Eric Lepage
Michel Blanc
Raoul Herbrecht
Andre ́ Bosly
Michel Attal
Georges Fillet
Catherine Guettier
Thierry Jo Molina
Christian Gisselbrecht

September 2016

We conducted a randomized trial to com-pare the intensive conventional chemo-therapy regimen ACVBP (...

CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma - a meta-analysis of randomized controlled trials

Vidal, Liat
Shpilberg, Ofer
Gurion, Ronit
Monsef, Ina
Raanani, Pia
Ram, Ron
Gafter-Gvili, Anat

January 2016

Background. R-CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma. ...

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study

Kluin-Nelemans, HC
Zagonel, V.
Anastasopoulou, A
Bron, D
Roozendaal, KJ
Noordijk, EM
Musson, H
Teodorovic, I.
Maes, B
Carbone, A
Carde, P

January 2001

Background: The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor....

Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin’s Lymphoma: Randomized Phase III EORTC Study

Hanneke C. Kluin-nelemans
Vittorina Zagonel
Anastasia Anastasopoulou
Dominique Bron
Klaas J. Roozendaal
M. Noordijk
Helen Musson
Brigitte Maes
Antonino Carbone
Patrice Carde
Jose ́ Thomas

July 2015

Background: The long-term outcome for patients with ag-gressive non-Hodgkin’s lymphoma (NHL) is poor...

Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMET) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma

Bailey, N. P.
Stuart, N. S. A.
Bessell, E. M.
Child, J. A.
Norfolk, D.
Fletcher, J.
Grieve, R. J.
Simmons, A. V.
Barnard, D. L.
Jack, A.
Farish, J.
Dunn, Janet A.
Woodroffe, C. M.
Stack, C.
Cullen, M. H.

June 1998

Background: Weekly alternating regimen known as CAPOMEt is compared to standard cyclical chemothera...

Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.

Wästerlid, Tove
Werner Hartman, Linda
Szekely, Erzsébet
Jerkeman, Mats

September 2015

No randomised study in the rituximab era has been performed specifically to evaluate addition of eto...

High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)

A. Wunderlich
M. Kloess
M. Reiser
C. Rudolph
L. Truemper
S. Bittner
H. Schmalenberg
R. Schmits
M. Pfreundschuh
M. Loeffler

January 2002

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for ...

Alternating CHOPB-POEMB chemotherapy for intermediate- and high-grade non-Hodgkin's lymphomas

Mizuta, Jun

December 1993

Between 1986 and 1991, 45 patients with intermediate- or high-grade non-Hodgkin's lymphoma, includin...

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Poeschel V.
Held G.
Ziepert M.
Witzens-Harig M.
Holte H.
Thurner L.
Borchmann P.
Viardot A.
Soekler M.
Keller U.
Schmidt C.
Truemper L.
Mahlberg R.
Marks R.
Hoeffkes H. -G.
Metzner B.
Dierlamm J.
Frickhofen N.
Haenel M.
Neubauer A.
Kneba M.
Merli F.
Tucci A.
de Nully Brown P.
Federico M.
Lengfelder E.
di Rocco A.
Trappe R.
Rosenwald A.
Berdel C.
Maisenhoelder M.
Shpilberg O.
Amam J.
Christofyllakis K.
Hartmann F.
Murawski N.
Stilgenbauer S.
Nickelsen M.
Wulf G.
Glass B.
Schmitz N.
Altmann B.
Loeffler M.
Pfreundschuh M.

January 2019

Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma

Tilly, H.
Lepage, E.
Coiffier, B.
Blanc, M.
Herbrecht, R.
Bosly, André
Attal, M.
Fillet, G.
Guettier, C.
Molina, TJ
Gisselbrecht, C.
Reyes, F.

January 2003

We conducted a randomized trial to compare the intensive conventional chemotherapy regimen ACVBP (do...

Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma

Burton, C.
Smith, P.
Vaughan-Hudson, G.
Qian, W.
Hoskin, P.
Cunningham, D.
Hancock, B.
Linch, D.

July 2005

CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) has been the standard chemotherap...

Two-Weekly or Three-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Young Patients with Good-Prognosis (Normal LDH) Aggressive Lymphomas: Results of the NHL-B1 Trial of the DSHNHL

Abstract

Extracted data

Related items

Related items